Pay in installments of $25.00 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Promo Codes Available:
For Your Every Summer RSVP, with Code: SUMMER15
Description
TNFRSF17/BCMA Recombinant Rabbit mAb (S-4674)Product Specification Host Rabbit Antigen TNFRSF17 BCMA Synonyms Tumor necrosis factor receptor superfamily member 17; B cell maturation protein; CD269 Location Cell membrane Accession Q02223 Clone Number S 4674 Antibody Type Recombinant mAb Isotype IgG Application WB, IHC P, ICC Reactivity Hu Positive Sample U266B1 Purification Protein A Concentration 0. 5 mg ml Conjugation Unconjugated Physical Appearance Liquid Storage Buffer PBS, 40% Glycerol, 0.
Product Specification
| Host | Rabbit |
| Antigen | TNFRSF17/BCMA |
| Synonyms | Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269 |
| Location | Cell membrane |
| Accession | Q02223 |
| Clone Number | S-4674 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB, IHC-P, ICC |
| Reactivity | Hu |
| Positive Sample | U266B1 |
| Purification | Protein A |
| Concentration | 0.5 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu |
| IHC-P | 1:100 | Hu |
| ICC | 1:500 | Hu |
Background
B-cell maturation antigen (BCMA, gene name TNFRSF17) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) that is specifically expressed on late-stage B-cell lineage cells, including plasmablasts and long-lived plasma cells, while being virtually absent in normal tissues or early B-cells. As a key receptor for both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), BCMA recruits TRAF adapter proteins to activate downstream signaling pathways such as NF-κB, MAPK, and PI3K/Akt, playing a central role in sustaining plasma cell survival, differentiation, and antibody secretion. Due to its highly restricted expression profile and its aberrant overexpression on multiple myeloma (MM) cells, BCMA has emerged as a premier therapeutic target; consequently, various BCMA-directed therapies, including chimeric antigen receptor T-cell (CAR-T) therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), have demonstrated remarkable clinical efficacy, fundamentally transforming the treatment landscape for this disease.
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy